
Durvalumab Plus FLOT May Not Significantly Increase AEs in Gastric Cancer
Most adverse effects (AEs) observed in previously published interim phase 3 MATTERHORN trial (NCT04592913) results, assessing durvalumab (Imfinzi) in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT), come from chemotherapy, …